Nov 28, 2019
The global varicella live vaccine market was valued at $2,714 million in 2018, and is expected to reach $4,222 million by 2026, registering a CAGR of 5.7% from 2019 to 2026
Jan 14, 2019
Saol Therapeutics Announces CDC has Updated Information Related to Use and Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])
Nov 26, 2018
NanoViricides Files Quarterly Report for Period Ending September 30, 2018
Oct 15, 2018
NanoViricides Has Filed its Annual Report, Company Reports Strong Progress in Advancement of HerpeCide Program
Sep 28, 2018
NanoViricides Inc. to Present at the MicroCap Conference in New York City on October 1
Sep 05, 2018
NanoViricides Inc. to Present at 20th Annual Rodman & Renshaw Conference in NYC on Sept 6th
Aug 07, 2018
NanoViricides Reports Its Topical Dermal Shingles Candidates Effective in Reducing Pain in Animal Study
Jun 26, 2018
Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research
May 22, 2018
NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates
May 01, 2018
Lawsuit Alleges Widely-Used Shingles Vaccine Caused Permanent Loss of Eyesight
Apr 09, 2018
NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today
Mar 27, 2018
Varicella Zoster Infection Treatment Market is Expected to Register a 4.2% CAGR From 2017 to 2027
Feb 21, 2018
NanoViricides Files Quarterly Report for Period Ending December 31, 2017
Dec 06, 2017
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
Nov 20, 2017
NanoViricides Files Quarterly Report for Period Ending September 30, 2017
Nov 06, 2017
NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
Oct 26, 2017
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center
Oct 25, 2017
Shingrix with QS-21 Stimulon® Receives Positive Recommendation from CDC's Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles
Oct 25, 2017
CDC's Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up
Oct 20, 2017
Shingrix approved in the US for prevention of shingles in adults aged 50 and over